Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > NCAM-1

NCAM-1

Brief Information

Name:Neural cell adhesion molecule 1
Target Synonym:Neural cell adhesion molecule 1,CD56,NCAM1,NCAM,Neural Cell Adhesion Molecule, NCAM,CD56 Antigen,N-CAM-1,MSK39,NCAM-1,Antigen Recognized By Monoclonal Antibody 5.1H11
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

NC1-HF256-ELISA
 NCAM-1 ELISA

Immobilized Anti-NCAM-1 Antibody, Human IgG1 at 5 μg/mL (100 μL/well) can bind FITC-Labeled Human NCAM-1, Fc Tag (Cat. No. NC1-HF256) with a linear range of 0.08-0.625 μg/mL (QC tested).

NC1-H5254-MALS-HPLC
NCAM-1 MALS images

The purity of Human NCAM-1 Protein, Llama IgG2b Fc Tag (Cat. No. NC1-H5254) is more than 90% and the molecular weight of this protein is around 245-285 kDa verified by SEC-MALS.

Synonym Name

CD56,MSK39,NCAM1,N-CAM-1

Background

NCAM1 belongs to the immunoglobulin superfamily of adhesion molecules. A wide range of alternatively spliced NCAM1 messenger RNAs (mRNAs) has been described to date, but only the 120-, 140-, and 180- kDa isoforms are commonly expressed. NCAM1 plays an important role in the regulation of neurogenesis, neurite outgrowth, proliferation, and cell migration, however, its function in hematopoiesis, including NK cells, is poorly understood. NCAM1 signaling is mediated either by homophilic or heterophilic interactions with fibroblast growth factor receptor (FGFR), L1-CAM, N-cadherin and other components of the extracellular matrix. Upon activation, NCAM1 triggers a variety of signaling cascades including FYN–focal adhesion kinase (FAK), MAPK, and phosphatidylinositol 3-kinase (PI3K) pathways.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
GD2/CD56 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) bi-4SCAR GD2/CD56 Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Neoplasms Details
Lorvotuzumab mertansine BB-10901; IMGN-901; huN-901-DM1; IMGN-901-TAP; huN-901-SPP-DM1 Phase 2 Clinical Immunogen Inc Rhabdomyosarcoma; Leukemia; Ovarian Neoplasms; Carcinoma, Merkel Cell; Wilms Tumor; Small Cell Lung Carcinoma; Sarcoma, Synovial; Multiple Myeloma; Neurofibrosarcoma; Neuroblastoma; Carcinoma, Small Cell Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message